L&T-TECHNOLOGY-SVCS
30.9.2021 20:29:13 CEST | Business Wire | Press release
L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a global leading pure-play engineering services company, today announced that its award-winning healthcare solution Chest rAI™ in collaboration with global technology leader Intel Corporation.
Chest rAI™ , LTTS’ AI-based chest X-Ray analysis system to assist radiologists in improving speed and accuracy of diagnosis, will be fueled by the Intel OpenVINO Toolkit and AI Analytics Toolkit to run optimized AI inferencing models on 3rd Gen Intel Xeon Scalable processors with built in AI accelerators.
LTTS’ AI-infused solution enables radiologists by fast triaging abnormalities in X-Ray, annotating and automatic report generation with significantly improved performance. The benefits of Chest rAI™ include increased throughput with the ability to extract more actionable information and to reduce waiting time for radiologists.
LTTS recently entered into a strategic engagement with one of the largest teleradiology platforms in India - 5C Network Private Limited, wherein 5C Network will leverage Chest rAI™ to empower radiologists with accurate patient insights while saving time.
Abhishek Sinha, Chief Operating Officer and Member of the Board, L&T Technology Services, said, “The potential of digital engineering in transforming complex age-old problem statements of the healthcare industry into simpler and more sophisticated mechanisms is now available to all, while maintaining patient data privacy by taking advantage of Intel hardware-enhanced security technologies. With more investments and by leveraging our engineering expertise in the medical image processing segment, our commitment is to enable a complete transformation of the Indian public health diagnostics services landscape. This collaboration will benefit millions of people not just in the urban but also in the rural areas.”
Sudhir Bahl, Board Member and Chief Strategy Officer, 5C Network, said, “Our endeavor is to serve as a reliable diagnostic partner with technology enabled decision-making for the healthcare service providers in India. As the next phase of growth, we aim to empower our radiologists with the best of futuristic technologies so that it not only enhances our quality but also empowers them with technology-based support to achieve clinical excellence with reduced turnaround time. With LTTS’ Chest rAI™ on Intel’s AI stack, we aim to reach elevated industry benchmarks.”
Intel’s AI Builders Program is an ecosystem of industry-leading independent software vendors (ISVs), system integrators (SIs), original equipment manufacturers (OEMs), and enterprise end users who want to accelerate the adoption of AI across Intel platforms.
Wei Li, VP and GM of Machine Learning Performance at Intel Corporation, said, “Wherever customers need AI, Intel is already there with 3rd Gen Intel Xeon Scalable processors and an optimized software stack for the complete AI pipeline. With investments in tools, technologies, and a worldwide ecosystem of optimized solutions, we’re making AI more accessible than ever. Through the Intel AI Builders Program, we collaborate with companies across the globe to help bring cutting-edge AI solutions and capabilities to market.”
LTTS’ capabilities on digital technology led new-age innovations for radiologists is industry-leading. Earlier this year, Chest rAI™ was honored by the US-based BIG Innovation Award as an acknowledgement of the path-breaking technology capability possessed by the solution.
To know more about LTTS’ Chest rAI™ solution click here:
https://www.ltts.com/solutions/healthcare/AI-radiography/chest-rAI
About L&T Technology Services Ltd
L&T Technology Services Limited (LTTS) is a listed subsidiary of Larsen & Toubro Limited focused on Engineering and R&D (ER&D) services. We offer consultancy, design, development and testing services across the product and process development life cycle. Our customer base includes 69 Fortune 500 companies and 57 of the world’s top ER&D companies, across industrial products, medical devices, transportation, telecom & hi-tech, and the process industries. Headquartered in India, we have over 16,900 employees spread across 17 global design centers, 28 global sales offices and 69 innovation labs as of June 30, 2021. For more information please visit https://www.ltts.com/ .
Intel, the Intel logo, and other Intel marks are trademarks of Intel Corporation or its subsidiaries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005907/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom